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ABSTRACT
INTRODUCTION: The HIV and TB co-epidemic remains a big obstacle in reducing PLHIV
mortality and morbidity in Namibia. The solution to that has been the implementation of
isoniazid preventative therapy (IPT) alongside ART for PLHIV to prevent the development of
active tuberculosis. As newer shorter regimens of IPT (3HP) are released it is important to
Namibia’s Ministry of Health to evaluate the efficacy of these newer IPT regimens prior to their
implementation.
OBJECTIVES: The objective of this review is to compare the benefit of 3HP to that of 6-month or
continuous (36-month) daily IPT for PLHIV to make future TB prophylaxis recommendations for
MOH of Namibia. The review will take into consideration outcomes such as TB incidence,
mortality, completion rate, and adverse events.
METHODS: The qualifying studies were randomized controlled trials which consisted of
participants being provided with 3HP and daily IPT (6 month or continuous). Only studies that
primarily enrolled PLHIV were included in this review. Out of all the results of these studies the
interest is in the development of active tuberculosis, mortality, adverse events, and treatment
completion rate.
RESULTS: The analysis of the two studies that qualified for this review informs us that 3HP has
similar efficacy in preventing active tuberculosis to that of IPT. The Sterling study reported that
discontinuation due to hepatotoxicity was significantly higher in the 9-month IPT arm (4%) than
in the 3HP (1%) arm. Hepatoxicity was reported in 1.4% (3/207) of the participants in the 3HP
group compared to 6.5% (12/193) of the 9-month IPT groups. Both studies reported a higher
completion and adherence rate for 3HP than for 6-month or 9-month IPT. The highest
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adherence was reported for the 3HP in the Martinson study at 95.7% whereas 6-month IPT had
an adherence rate for only 83.8%.
CONCLUSION: Largely, this review suggests that further research be done to evaluate the
complexity of 3HP in different settings with different populations. However, based on these
preliminary findings it is preferable for Namibia to adopt 3HP once it is cost-effective to raise
their IPT completion rates, increase implementation of IPT in all local sites, and prevent adverse
outcomes.
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I.

BACKGROUND

WHAT IS TUBERCULOSIS?
Tuberculosis (TB) is one of the top ten leading causes of death worldwide due to a single
infectious agent. In 2018 alone, it was responsible for killing 1.5 million people with 10 million
people experiencing the illnessi. In addition to affecting so many around the world it can be
found in all countries despite being a preventable disease. In an ideal world timely diagnosis
and treatment would be available to all thus drastically reducing transmission and severity of
the illness. However, due to the lengthy treatment and lack of feasible diagnostic measures that
is not necessarily the case. The eradication of TB is complicated by the route of transmission of
the bacteria as well as the latent stage of the disease. A latently infected individual will not
develop any of the symptoms associated with the illness, and of the latently infected individuals
5-10% will go on to develop the disease. Currently, almost 1.7 billion people around the world
are infected with TB and thus are at risk for active tuberculosisi. People with the disease
typically exhibit unexplained weight loss, lack of appetite, night sweats, fever and chills. Those
with pulmonary tuberculosis will additionally develop chest pain, persistent cough and
hemoptysis. Those exhibiting symptoms are considered infectious and capable of spreading the
TB bacteria to others. Thus, it is imperative to minimize the development of disease especially
for the immunosuppressed.

In 2018, the TB burden in Namibia was 0.524% (524/100,000) with the mortality at
0.064% (64/100,000) ii. However, this number does not capture the whole story of TB associated
mortality. Out of the 13,000 individuals affected with TB, 4500 were HIV-positiveii. The fact that
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36% of TB patients have an HIV-positive status is alarming. Globally, Namibia remains one of
the most HIV prevalent countries. In 2018, the prevalence of HIV in the country was at 11.8%
with 2,400 AIDS related deathsii. This highlights that there is a large population of people living
with HIV (PLHIV) that are vulnerable to developing tuberculosis. The co-epidemic of HIV and
tuberculosis (TB) remains a major public health crisis.

WHY ARE TB AND HIV SO INTERLINKED?
The human immunodeficiency virus (HIV) is an infection in which the CD4 T-lymphocytes
are targeted. By preferentially targeting the CD4 lymphocytes the immune system is left
weakened. For someone living with HIV the risk of developing TB is 20-37 times greater than for
those that are HIV negativeiii. For an HIV negative individual, the risk progressing from latent TB
to active TB is 10%, but for PLHIV this risk is 30% iv. Thus, HIV remains the strongest risk factor
for TB disease progression and severity. An HIV infection increases one’s risk of latent TB
reactivation. Individuals suffering from a TB and HIV co-infection experience faster disease
progression rates and have a higher risk of mortality. There is an inverse relationship between
CD4 lymphocyte count and risk of active TB, as CD4 cell count declines the risk for active TB
increases. Numerically, this relationship is seen as a 15-20% increased risk of active TB per year
for PLHIV with CD4 cell counts of less than 200 cells/lv. In areas of high prevalence of HIV there
remains a need to implement TB control measures in order to keep PLHIV protected as well as
stop the TB epidemic.

WHAT ARE THE CURRENT TREATMENT MEASURES FOR PLHIV?
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In order to assess the need for further prophylaxis, it is important to first analyze what
measures are currently implemented for PLHIV. Through PEPFAR there has been a global scaleup of HIV care all over Africa. This scale-up includes treatment services, in particular,
antiretroviral therapy (ART). PEPFAR is currently implemented in Namibia for three strategic
areas; prevention of HIV transmission, care and treatment of PLHIV, and strengthening the
public health system to effectively and sustainably respond to the epidemic vi. Through PEPFAR,
Namibia is trying to achieve the UNAIDS 90-90-90 targetsvii. These targets will ensure that 90%
of all PLHIV know their status, 90% of those who know their status are on ART and lastly 90% of
those on treatment are able to achieve viral suppressionviii. The second 90 is important because
it is concerning treatment for PLHIV with ART. Currently, all PLHIV in Namibia are eligible for
ART upon being diagnosed. Those with a positive HIV test are referred to an ART clinic to be
further assessed and to begin the ART regimen. All this effort has given significant results
because as of 2018, 76.5% of PLHIV are on ART and 87% of those on ART have viral suppression.
This is proof that Namibia is on its way to achieve the UNAIDS 90-90-90 targets. ART is also
known to be associated with rapid recovery of mycobacteria-specific immune responses. This
leads to decreased mycobacterial growth and at the clinical level has shown to be a powerful TB
preventative effect. Since the advent of ART, analysis has shown there to be 65% reduction in
TB incidence in PLHIV.

WHAT IS ISONIAZID PREVENTION THERAPY?
However, due to the increased risk of tuberculosis for PLHIV there is a need for more
prophylaxis beyond just antiretroviral therapy. Moreover, TB rates still remain relatively high
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even after increasing ART uptake among PLHIV; thus, highlighting the need for continued focus
on TB control measures. Currently, ART is accompanied by the implementation of isoniazid
preventative therapy (IPT). IPT has been widely used as prevention for TB. It eliminates the
bacterium from the body by treating latent tuberculosis and preventing new infections from
occurring during treatmentix. Alongside ART, IPT provides an additional blanket of protection
for PLHIV to prevent tuberculosis. Several studies show that IPT alongside ART provides
additional benefits in lowering the incidence of TB than just the implementation of ART alone x.
(Table 1)

Table 1- List of IPT + ART vs ART alone studies
Study
Type
Edessa 2015iii
Retrospective cohort study at
TASH and ZMH 6-month IPT +
ART and ART alone
Badje, TEMPRANO ANRS
RCT for 6-month IPT + ART in
xi
12136, 2017
Cote d’Ivore
xii
Golub, THRio, 2007
Prospective cohort; Brazil

Golub, 2009xiii

Prospective cohort; South
Africa

Yirdaw, 2014xiv

Retrospective cohort;
Ethiopia

Rangka, 2014xv

RCT; South Africa

Table 2- List of continuous IPT vs 6-month IPT studies
Study
Type
xvi
Samandari, 2011
RCT; Botswana

Key findings
For ART alone TB incidence:
10/100 PY, For IPT + ART TB
incidence: 4.5/100 PY
35% reduction in HIV related
deaths after initiation of IPT
For ART alone TB incidence:
1.9/100 PY, For IPT + ART TB
incidence: 0.8/100 PY
For ART alone TB incidence:
4.6/100 PY, For IPT + ART TB
incidence: 1.1/100 PY
For ART alone TB incidence:
0.74/100 PY, For IPT + ART TB
incidence: 0.36/100 PY
For ART alone TB incidence:
3.6/100 PY, For IPT + ART TB
incidence: 2.3/100 PY

Key findings
6-month IPT: 34 cases/989
participants (3.4%)
Continuous IPT: 20
cases/1006 (2.0%)
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Kunkel, 2016xvii

Transmission Dynamic
Model; Botswana

Swaminathan, 2012xviii

RCT; India

Hsieh, 2018xix

Transmission Dynamic
Model, Malawi

Benefits of continuous IPT
outweigh the risk of long
duration of IPT in reduction
of TB incidence and
mortality.
Both regimens were similarly
effective, 36 months showed
a lower trend of TB
incidence.
6 months: 2.4/100py
Continuous IPT: 1.6/100py
Compared to the 6-month
IPT program, the continuous
IPT can avert at least 6902
more TB cases and prevent
2256 deaths.

Through the analysis of these studies it is clear that when ART is combined with IPT
there is greater reduction of mortality for PLHIV. This is due to the fact that IPT lowers the risk
of active tuberculosis in high endemic settings for those that are extremely vulnerable (PLHIV).
Thus, WHO recommends that IPT be given to all PLHIV in combination with ART starting at the
time of diagnosisix.
The current recommendation is that IPT be given continuously for at least 6 months.
Additionally, in high TB endemic areas it is recommended that IPT be given for 36 continuous
months. For example, in countries like Botswana, where incidence of TB is at 350 per 100,000, 6
months of IPT can be insufficient. In a randomized, double-blind, placebo-controlled trial
conducted in Botswana it was discovered that 36 months of continuous IPT given to PLHIV
reduced TB incidence by 43% when compared to 6 months of IPTxvi. It should be noted that this
benefit was seen in those with a tuberculin positive test. (39) The Swaminathan randomized
clinical trial in India had similar findings in which 712 PLHIV were randomized to receive either
6-month IPT or continuous IPT (36 months) xviii. The results showed a decreased TB incidence for
10

continuous IPT when compared to 6-month IPT (6 months: 2.4/100py, continuous IPT:
1.6/100py).
In comparison the TEMPRANO study conducted in West Africa, where the incidence of
TB in 159 per 100,000 people, concluded that 6 months of ART + IPT has durable protective
effect in reducing mortality in PLHIV when taken along with ARTxi. After the analysis of current
available studies, it can be concluded that the length of IPT is context-specific and can be
proportional to the burden of tuberculosis in the country ix. (Table 2)
While 6-month IPT is part of the current WHO guidelines for TB prophylaxis there is
another treatment option of 3-month weekly regimen of rifapentine plus isoniazid (3HP) that is
recommended for high- or upper-middle-income countries with a TB incidence of
<100/100,000. The shorter duration and simplicity offered by the 3 month-once weekly
regimen has major appeal for the future of IPT. Since the advent of 3HP in 2011, many studies
have confirmed 3HP’s effectiveness when compared to alternative IPT regimensi.
Since 3HP, an even shorter course regimen of daily isoniazid and rifapentine for 28 days
(1HP) has been formulated. Due to its extremely short regimen it will have even fewer barriers
towards implementation and completion rate than 3HP. This shorter regimen is not currently
available to be implemented and this will not be further discussed in this reviewi.

OBJECTIVE:
The objective of this review is to compare the benefit of 3HP to that of 6-month or
continuous (36-month) daily IPT for PLHIV to make future TB prophylaxis recommendations for
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Namibia. The review will take in consideration outcomes such as TB incidence, mortality,
completion rate, and adverse events.

II.

METHODS

ETHICS STATEMENT:
Ethical approval was not required for this review.

SEARCH STRATEGY:
The search was conducted on the PubMed electronic database. The strategy was to use the
terms IPT, rifapentine, 3HP, PLHIV, and RCT. The search was limited to those that were
randomized controlled trials and the search span included studies that were published between
1 January 2011 and 1 January 2019. This was done so all studies that were done after the
introduction of 3HP can be evaluated. The reference lists of included papers were also checked
and reviewed to get additional studies. No language or geographical limitations were applied.

ELIGIBILITY CRITERIA:
The qualifying studies were randomized controlled trials which consisted of participants being
provided with 3HP and daily IPT (6 month or continuous). Only studies that primarily enrolled
PLHIV were included in this review. Out of all the results of these studies the interest is in the
development of active tuberculosis, mortality, adverse events, and treatment completion rate.
For the purposes of this review the 6-month IPT and 9-month IPT regimen were considered
equivalent. Information taken from each article included study design, comparison groups,
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number of participants, and the impact of the intervention through risk ratios. There is however
extensive heterogeneity between the study populations, study methods and settings which
needs to be taken into consideration when drawing any conclusions xx.

Table 3- List of included studies in this review
Study
Country
xxi
Martinson, 2011
South Africa

Sterling, 2016xxii

USA, Canada, Brazil, Spain,
Hong Kong, and Peru

Participants
3HP: 328
6H: 327
Continuous IPT: 164
3HP: 206
9H*: 193

* For the purposes of this review the 6-month IPT and 9-month IPT regimen were considered equivalent.

III.

RESULTS
The studies (Table 3) included in this analysis have been analyzed in prior reviews. Since

the last systematic review there has not been another study that qualifies for this analysis.
However, this review will focus on outcomes of interest (TB incidence, mortality, adverse
events, and completion rate) and then will proceed to discuss the feasibility of implementation
of 3HP in the Namibia setting.

DESCRIPTION OF INCLUDED STUDIES:
Martinson et al•

The study included randomly assigned South African adults with HIV infection. All
participants had a positive tuberculin test and were not initiated on ART. The study arms
were: rifapentine (900 mg) and isoniazid (900 mg) weekly for 12 weeks (3HP), rifampin
(600 mg) and isoniazid (900 mg) twice weekly for 12 weeks (3HP-2), isoniazid (300 mg)
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daily for up to 6 years (continuous isoniazid), and isoniazid (300 mg) daily for 6 months
(6-month IPT control group).
•

Study population was a Soweto community with high prevalence of HIV infection and
tuberculosis. The eligible participants were at least 18 years of age, were not pregnant
of breast feeding and did not have active tuberculosis that was ruled out both through a
comprehensive symptom review and through chest radiography. Patients that had
previously received tuberculosis preventative therapy were excluded from the study.

•

Treatment for the 3HP & 3HP-2 regimen was directly observed in study clinics while the
6-month and continuous IPT were self-administered. Patients were assigned in a
randomly generated algorithm format in 2:2:2:1 block for the 4 treatments groups of
3HP, 3HP-2, 6-month IPT and continuous IPT, respectively.

Sterling et al•

An open-label, randomized noninferiority trial that compared once-weekly rifapentine
600–900 mg plus isoniazid given under direct observation(3HP) with self-administered
9-month daily IPT for participants at high risk for tuberculosis.

•

Participants from the United States, Spain, Brazil, Canada and Hong Kong were enrolled
from June 2001 and December 2010, additionally participants from Peru and Brazil were
enrolled from February 2008 and December 2010. The participants were followed
through September 2013. HIV testing was only recommended and not enforced for the
enrollment for this trial. Patients (≥ 2 years) with an HIV infection and a positive
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tuberculin test (or had close contact with an active tuberculosis case) were enrolled in
the study.
•

Treatment was allocated in randomized fashion. For household clusters, the first person
in the group was randomized to an intervention and the same treatment was given to
the rest of the cluster. Those with a suspected positive case of tuberculosis, previous
isoniazid therapy, pregnant or breastfeeding were excluded from the study. Participants
were followed for 33 months from enrollment and went through a monthly evaluation
process. After completion of therapy study visits occurred every 3 months up until the
21st month.

TB INCIDENCE AND MORTALITY:
Table 4- TB incidence and mortality Martinson et al.
Incidence
3HP
3HP-2
Continuous IPT
Cases
24
24
8
PY follow up
1187.5
1219.7
561.0
Incidence rate
2.0
2.0
1.4
per 100 PY
Mortality
Deaths
PY follow up
Incidence rate
per 100 PY

3HP
17
1223.6
1.4

3HP-2
16
1269.8
1.3

Continuous IPT
8
574.2
1.4

6-month IPT
22
1143.9
1.9

All
78
4112.1
1.9

6-month IPT
25
1180.0
2.1

All
66
4247.6
1.6

The incidence rate of tuberculosis incidence and mortality was not significantly different
between the 3HP and 6-month IPT groups. The incidence rate-ratio for incidence and mortality
of 3HP was 0.87 when compared to the reference of 6-month IPT (1.0). The p-value was 0.54
signaling that there was no statistically significant difference between the two regimens. In
total tuberculosis was diagnosed for 78 patients of which 62 had a confirmed tuberculosis, 11
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had probable tuberculosis and 5 had possible tuberculosis. Out of the all participants, 66
patients died during the follow-up. No significant differences in the incidences of tuberculosis
or death was seen between all three shorter regimen treatment groups. The rate of
tuberculosis and mortality was lower in the continuous isoniazid groups than in the other three
groups. (Table 4)

Table 5- TB incidence and mortality Sterling et al.
TB Incidence
3HP
Total Participants
206
TB cases
2
Incidence rate per 100 PY
0.39

9-month IPT
193
6
1.25

There were 2 tuberculosis cases in the 3HP arm in the 517 person-years of follow up and 6
tuberculosis cases in the 481 person-years of follow up for the 9-month IPT arm. Since this was
a non-inferiority trial the margin for non-inferiority was defined as the difference in cumulative
TB rates of 0.75%. Non-inferiority was reached within the modified intention-to-treat analysis
(upper limit of the 95% CI 0.60). Non-inferiority was not reached in the per-protocol analysis
(upper limit of the 95% CI 1.47). A previous systematic review conducted a meta-analysis which
failed to show a significant difference in the risk for active TB between the two treatment
groups. Additionally, there was no significant difference in mortality between the 3HP and 9month IPT for adults with HIV.

ADVERSE EVENTS:
Martinson et al -
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The shorter regimens (3HP, 3HP-2, 6-month IPT) all had adverse events likely to occur after the
completion of the treatment whereas the continuous regimen saw 87.3% of adverse events
occurring in duration of the medication phase. Serious adverse events included grade 3 or 4
toxic effects, death and active tuberculosis. For 3HP arm the rate of adverse events was 8.7 per
100 PY, 3HP-2 had a rate of 10.6 per 100 PY, continuous isoniazid group had a rate of 18.4 per
100 PY and 15.4 per 100 PY for the 6-month isoniazid group. No deaths were reported from the
drug regimen itself. This study did report an increase in aspartate or alanine aminotransferase
levels during treatment phase. The proportion of participants experiencing this increase was
1.5% in 3HP, 2.4% in 3HP-2, 28% in continuous IPT and 5.5% in 6-month IPT.

Sterling et al Discontinuation due to hepatotoxicity was significantly higher in the 9-month IPT arm (4%) than
in the 3HP (1%) arm. Hepatoxicity was reported in 1.4% (3/207) of the participants in the 3HP
group compared to 6.5% (12/193) of the 9-month IPT groups. A significantly lower risk of
hepatoxicity is present in participants taking 3HP than in those taking 9-month IPT. The risk of
grade 3 or 4 adverse was also lower in patients given 3HP over 9-month IPT regimen.

COMPLETION RATE:
Both studies reported a higher completion and adherence rate for 3HP than for 6-month or 9month IPT. The highest adherence was reported for the 3HP in the Martinson study at 95.7%
whereas 6-month IPT had an adherence rate for only 83.8%. In the Sterling study treatment
completion was significantly higher in the 3HP arm than in the 9-month arm. In the 3HP arm
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89% (183/206) reported completion whereas only 64% (123/193) reported treatment
completion in 9-month IPT arm. This was a statistically significant result as the p-value was less
than 0.001. Since there is heterogeneity between the two studies regarding the length of the
IPT regimens they are not fully comparable. The point worth noting is that both studies favored
3HP for adherence and completion no matter what it was being compared toxx.

IV.

DISCUSSION
The objective of this review was to assess the efficacy of 3HP as an alternative

tuberculosis prophylaxis regimen to 6-month IPT. This is an important public health question
because for many countries that have high HIV and tuberculosis burden the benefits offered by
a shorter and simpler regimen can reduce morbidity and mortality associated with an active
tuberculosis infection.
Although, IPT has been a World Health Organization (WHO) recommendation for PLHIV
and children <5 years exposed to persons with TB since 1993, global IPT uptake has remained
slow. Of the 34.5 million adults living with HIV, only 4.8 million (14%) were ever reported to
have been started on IPT since 1993xxiii. Namibia’s 2016 HIV Guidelines recommends that all
PLHIV in whom TB disease has been excluded should receive 9 months of IPT. Under the U.S.
President’s Emergency Plan for AIDS Relief, of the 176,126 PLHIV currently receiving ART in
Namibia, only 41,612 are recorded as having completed a course of IPT between the end of
2014 and mid 2019. This suggests that 134,514 PLHIV in Namibia remain untreated. Namibia’s
2020 PEPFAR target for the number of PLHIV that are expected to complete TPT is 82,042. To
achieve this ambitious goal, programmatically a more feasible approach that delivers treatment
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widely and successfully will need to be implemented. One avenue is to explore utilizing the
isoniazid-rifapentine (3HP) regimen. The shorter course of therapy offers the prospect of
improving acceptance and adherence most notably increasing completion rates of IPT in a
programmatic setting.

CURRENT IMPLEMENTATION OBSTACLES:
There are many obstacles to IPT implementation, the foremost being adherence to
treatment and adverse events.
Adherence is difficult to achieve for the IPT regimen in place today due to the length
and rigidness of the therapy. Once a patient starts to feel well it is hard to adhere to a regimen
that requires months to complete. In countries worldwide IPT completion rates are between
37% to 95% due to issues with adherence. Namibia faces this issue as well since many of their
local sites are below 85% for IPT completion rates. Poor adherence essentially negates any
benefit IPT might provide to the patient xxiv. In order to maximize efficacy of the regimen it is
important that adherence and completion of the therapy remain a top priority. As discussed in
the results section of this review both studies reported higher completion and adherence rates
for 3HP when compared to either the 6 or 9-month IPT with statistical significance. The Sterling
study is comparable to Namibia because it compared 3HP to 9-month IPT (which is the WHO
recommendation for Namibia). In the study, the 9-month IPT arm only reported 64%
completion whereas 3HP was at 89%. This is evidence that if 3HP is implemented in Namibia
the current completion issues faced by the country can be somewhat alleviated. It is worth
considering the differences between the setting of the Sterling study and Namibia when
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drawing any conclusions. However, the future of IPT still looks optimistic if we take into
consideration the available study data regarding 3HP.
Another notable obstacle in the success of isoniazid preventative therapy is the onset of
adverse events. There notable toxicities associated both with isoniazid and ART which make it
difficult to understand the causative agent when adverse events occur for PLHIV on IPT xxi. The
worst adverse event is isoniazid associated hepatotoxicity. Isoniazid can cause an elevation in
liver enzymes, however if it is less than three times the normal amount it is resolvable. This can
usually be mitigated through cessation of regimen. The risk for hepatoxicity increases with age,
immunosuppression, hepatitis and consumption of alcohol. Per the WHO recommendations the
participants must be thoroughly screened and monitored to avoid cases of hepatoxicity.
However, such monitoring is not always available leaving PLHIV on IPT vulnerable to the onset
of adverse events. In both of the studies analyzed in this review lower hepatoxicity was
reported in the 3HP arm than in the 6-month or 9-month IPT arm. Additionally, fewer people
discontinued the medication due to hepatoxicity in the 3HP arm than in the 6-month or 9month IPT arm. While more studies are needed to fully assess the hepatoxicity of isoniazid
therapy it is clear that taking a potentially strong medication in fewer doses for a shorter
regimen is preferable to taking it daily for 6-36 months. Thus, to promote both adherence and
reduce hepatoxicity implementing 3HP in place of 9-month IPT in Namibia is a worthwhile
endeavor.
Due to its shorter regimen it can additionally be noted that in countries, including
Namibia, where implementation of IPT has been slow 3HP may provide a benefit in
reinvigorating the TB prevention treatment program.
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EFFICACY:
In terms of efficacy it is clear that 3HP has a similar efficacy in preventing active TB when
compared to daily isoniazid therapy through the analysis of onset of tuberculosis cause and allcause mortality. As discussed it is not only more efficacious but also has a higher treatment
completion rate and fewer adverse events. When discussing efficacy, it only applies when
comparing 3HP to 6 or 9-month IPT and not continuous IPT. Another systematic review along
with a modeling study has reported a lower risk of tuberculosis among participants receiving
continuous IPT in the place of 6-month IPT. Thus, further research is needed when deciding
between 3HP and continuous IPTxx.

COST-EFFECTIVENESS:
One of the biggest challenges in implementing 3HP is the price. The cost of rifapentine is
higher than that of isoniazid. Additionally, since this regimen is not self-administered there is an
additional cost associate with directly observed therapy (DOT). The need for additional personal
for DOT is a barrier to implementation due to cost and training required. The more flexibility
available for any prophylaxis regimen the higher the adherence and lower the discontinuation
of the medication. The price of rifapentine is $6 per dose in the United States, but the price for
the countries in need is still far from being cost-effective. Until a decrease in the price is
negotiated it remains a huge barrier in broad implementation of 3HP in Namibiaxx.

LIMITATIONS:
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There are significant limitations in this analysis. In order to provide accurate
recommendation for Namibia a 3HP randomized controlled trial needs to be conducted in a
similar environment with a similar population. Secondly, the last trial was conducted four years
ago, and thus newer data is required to confirm the findings from the previous studies.
Additionally, data on children with HIV is limited and thus the conclusions drawn from this
review is not applicable on that population. Lastly, there are studies available on the added
benefit of continuous IPT. Thus, in order to attain information on how 3HP performs against
continuous IPT further studies need to be conducted.

V.

CONCLUSION
The analysis of the two studies that qualified for this review inform us that 3HP has similar

efficacy in preventing active tuberculosis to that of IPT. In addition, it is also noted that from the
data collected in the two studies there are fewer adverse events and higher adherence in the
participants receiving 3HP compared to the other regimens. The discussed limitations identify a
gap in research regarding the effectiveness of 3HP to that of continuous IPT. Largely, this review
suggests that further research be done to evaluate the complexity of 3HP in different settings
with different populations. However, based on these preliminary findings it is preferable for
Namibia to adopt 3HP once it is cost-effective to raise their IPT completion rates, increase
implementation of IPT in all local sites, and prevent adverse outcomes.
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